PT  - JOURNAL ARTICLE
AU  - Hagedoorn, Nienke N.
AU  - Murthy, Shruti
AU  - Birkhold, Megan
AU  - Marchello, Christian S.
AU  - Crump, John A.
AU - Vacc-iNTS Consortium
TI  - Prevalence and distribution of non-typhoidal <em>Salmonella enterica</em> serogroups and serovars isolated from normally sterile sites: a global systematic review
AID  - 10.1101/2023.06.13.23291315
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.13.23291315
4099  - http://medrxiv.org/content/early/2023/06/13/2023.06.13.23291315.short
4100  - http://medrxiv.org/content/early/2023/06/13/2023.06.13.23291315.full
AB  - To inform vaccine development strategies, we aimed to systematically review evidence on the prevalence and distribution of non-typhoidal Salmonella enterica serogroups and serovars. We searched four databases from inception through 4 June 2021. We included articles that reported at least one non-typhoidal Salmonella enterica strain by serogroup or serovar isolated from a normally sterile site. Of serogrouped isolates, we pooled the prevalence of serogroup O:4, serogroup O:9, and other serogroups using random-effects meta-analyses. Of serotyped isolates, we pooled the prevalence of Salmonella Typhimurium (member of serogroup O:4), Salmonella Enteritidis (member of serogroup O:9), and other serovars. Of 82 studies yielding 24,258 serogrouped isolates, pooled prevalence (95% CI) was 44.7% (36.3%-48.3%) for serogroup O:4, 45.4% (36.9%-49.0%) for serogroup O:9, and 9.9% (6.1%-13.3%) for other serogroups. Pooled prevalence (95%CI) was 36.8% (29.9%-44.0%) for Salmonella Typhimurium, 37.8% (33.2%-42.4%) for Salmonella Enteritidis, and 18.4% (11.4%-22.9%) for other serovars. Of global serogrouped non-typhoidal Salmonella isolates from normally sterile sites, serogroup O:4 and O:9 together accounted for 90%. Of global serotyped isolates, serovars Typhimurium and Enteritidis together accounted for 75%. Vaccine development strategies covering serogroups O:4 and O:9, or serovars Typhimurium and Enteritidis, have the potential to prevent the majority of non-typhoidal Salmonella invasive disease.PROSPERO:CRD42022376658.Key resultsInvasive infections in normally sterile sites caused by non-typhoidal Salmonella have a case fatality ratio of 15%.Vaccine products for human non-typhoidal Salmonella are in currently in development.For future vaccine strategies, we provide global non-typhoidal Salmonella serogroup and serovar coverage by region and by age groups.Serogroups O:4 and O:9 account for 90% of isolates of non-typhoidal Salmonella enterica from normally sterile sites.Serovars Typhimurium and Enteritidis, members of serogroup O:4 and O:9, respectively, cover 75% of isolates of non-typhoidal Salmonella enterica from normally sterile sites.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=376658 Funding StatementThis project has received funding from the EU Horizon 2020 research and innovation programme under the project Vacc-iNTS (grant agreement number 815439).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData underlying this study will be made available upon acceptance of publication in a repository.GMMAGeneralized Modules for Membrane AntigensNTSnon-typhoidal SalmonellaPROSPEROProspective Register of Systematic ReviewsUNUnited Nations